Ian L Megson

List of Publications by Year
in descending order

151 papers	10,541 citations	38742 50 h-index	36028 97 g-index

158 all docs	158 docs citations	158 times ranked	15119 citing authors

#	Article	IF	Citations
1	Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrastâ€Induced Nephropathy: A Failure of Academic Clinical Science. Clinical Pharmacology and Therapeutics, 2022, 111, 1222-1238.	4.7	4
2	Intermittent exposure of cultured endothelial cells to physiologically relevant fructose concentrations has a profound impact on nitric oxide production and bioenergetics. PLoS ONE, 2022, 17, e0267675.	2.5	1
3	Measurement of Heart Rate Using the Polar OH1 and Fitbit Charge 3 Wearable Devices in Healthy Adults During Light, Moderate, Vigorous, and Sprint-Based Exercise: Validation Study. JMIR MHealth and UHealth, 2021, 9, e25313.	3.7	34
4	Does oxidative stress contribute to toxicity in acute organophosphorus poisoning? â€“ a systematic review of the evidence. Clinical Toxicology, 2020, 58, 437-452.	1.9	16
5	P0917N-ACETYL CYSTEINE FAILS TO IMPACT ON PLASMA ANTIOXIDANT CAPACITY IN BOTH A PLACEBO CONTROLLED CROSSOVER STUDY AND A PARALLEL GROUP TRIAL OF PATIENTS WITH CKD STAGE III: IMPLICATIONS FOR ITS USE AS A PROPHYLACTIC FOR CONTRAST INDUCED NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
6	The impact of glucose exposure on bioenergetics and function in a cultured endothelial cell model and the implications for cardiovascular health in diabetes. Scientific Reports, 2020, 10, 19547.	3.3	15
7	Antibacterial efficacy from NO-releasing MOFâ€“polymer films. Materials Advances, 2020, 1, 2509-2519.	5.4	18
8	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. Frontiers in Cardiovascular Medicine, 2020, 7, 629933.	2.4	43
9	Reactive Oxygen Species (ROS), Intimal Thickening, and Subclinical Atherosclerotic Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 89.	2.4	74
10	Synthesis of novel vanillin derivatives: novel multi-targeted scaffold ligands against Alzheimer's disease. MedChemComm, 2019, 10, 764-777.	3.4	28
11	RW3â€…Hyperglycaemia induces reversible changes to metabolism and cell function in cultured endothelial cells: implications for the link between diabetes and cardiovascular disease. , 2019, , .		0
12	P7â€…Consumption of antioxidant-rich drinks does not protect against endothelial dysfunction associated with a high-calorie meal challenge. , 2019, , .		0
13	Co-ingestion of Antioxidant Drinks With an Unhealthy Challenge Meal Fails to Prevent Post-prandial Endothelial Dysfunction: An Open-Label, Crossover Study in Older Overweight Volunteers. Frontiers in Physiology, 2019, 10, 1293.	2.8	6
14	Radial artery access site complications during cardiac procedures, clinical implications and potential solutions: The role of nitric oxide. World Journal of Cardiology, 2019, 12, 26-34.	1.5	15
15	Mitochondrial ROS cause motor deficits induced by synaptic inactivity: Implications for synapse pruning. Redox Biology, 2018, 16, 344-351.	9.0	43
16	Novel vanillin derivatives: Synthesis, anti-oxidant, DNA and cellular protection properties. European Journal of Medicinal Chemistry, 2018, 143, 745-754.	5.5	28
17	Associations between circulating IgG antibodies to Apolipoprotein B100-derived peptide antigens and acute coronary syndrome in a Chinese Han population. Bioscience Reports, 2018, 38, .	2.4	2
18	To clot or not to clot? That is a free radical question. Journal of Physiology, 2018, 596, 4805-4806.	2.9	0

#	Article	IF	Citations
19	Bioactive polyphenols and cardiovascular disease: chemical antagonists, pharmacological agents or xenobiotics that drive an adaptive response?. British Journal of Pharmacology, 2017, 174, 1209-1225.	5.4	117
20	Bioavailable Concentrations of Delphinidin and Its Metabolite, Gallic Acid, Induce Antioxidant Protection Associated with Increased Intracellular Glutathione in Cultured Endothelial Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-17.	4.0	44
21	Preliminary study of hypoxia-related cardiovascular mediator-markers in patients with end-stage renal disease with and without diabetes and the effects of haemodialysis. PLoS ONE, 2017, 12, e0178171.	2.5	2
22	Lipids and cardiovascular disease: where does dietary intervention sit alongside statin therapy?. Food and Function, 2016, 7, 2603-2614.	4.6	22
23	The acute (immediate) effects of reflexology on arterial compliance in healthy volunteers: A randomised study. Complementary Therapies in Clinical Practice, 2016, 22, 16-20.	1.7	7
24	Tuning the nitric oxide release from CPO-27 MOFs. RSC Advances, 2016, 6, 14059-14067.	3.6	55
25	Iodixanol Has a Favourable Fibrinolytic Profile Compared to Iohexol in Cardiac Patients Undergoing Elective Angiography: A Double-Blind, Randomized, Parallel Group Study. PLoS ONE, 2016, 11, e0147196.	2.5	1
26	Detection of circulating IgG antibodies to apolipoprotein B₁₀₀ in acute myocardial infarction. FEBS Open Bio, 2015, 5, 712-716.	2.3	6
27	Antioxidants in Cardiovascular Therapy: Panacea or False Hope?. Frontiers in Cardiovascular Medicine, 2015, 2, 29.	2.4	130
28	Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 573-580.	2.2	8
29	A study of IgG antibodies to the ApoB protein in non-ST segment elevation acute coronary syndrome. Scandinavian Cardiovascular Journal, 2015, 49, 136-141.	1.2	2
30	12-hydroxyeicosatetraenoic acid is associated with variability in aspirin-induced platelet inhibition. Journal of Inflammation, 2014, 11, 33.	3.4	20
31	Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. , 2014, 141, 150-159.		502
32	Oatâ€enriched diet reduces inflammatory status assessed by circulating cellâ€derived microparticle concentrations in type 2 diabetes. Molecular Nutrition and Food Research, 2014, 58, 1322-1332.	3.3	33
33	Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. Journal of Thrombosis and Thrombolysis, 2014, 37, 455-463.	2.1	63
34	Surface functionalization affects the zeta potential, coronal stability and membranolytic activity of polymeric nanoparticles. Nanotoxicology, 2014, 8, 202-211.	3.0	82
35	Principal component and causal analysis of structural and acutein vitrotoxicity data for nanoparticles. Nanotoxicology, 2014, 8, 465-476.	3.0	57
36	The 2011 Survey on Hypertensive Disorders of Pregnancy (HDP) in China: Prevalence, Risk Factors, Complications, Pregnancy and Perinatal Outcomes. PLoS ONE, 2014, 9, e100180.	2.5	133

#	Article	IF	Citations
37	Endothelial cell oxidative stress in diabetes: a key driver of cardiovascular complications?. Biochemical Society Transactions, 2014, 42, 928-933.	3.4	31
38	Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. Bioorganic and Medicinal Chemistry, 2013, 21, 2107-2116.	3.0	12
39	A randomized crossover study to assess the effect of an oatâ€rich diet on glycaemic control, plasma lipids and postprandial glycaemia, inflammation and oxidative stress in Type 2 diabetes. Diabetic Medicine, 2013, 30, 1314-1323.	2.3	37
40	Predictive value of in vitro assays depends on the mechanism of toxicity of metal oxide nanoparticles. Particle and Fibre Toxicology, 2013, 10, 55.	6.2	104
41	A new class of NO-donor pro-drugs triggered by Î³-glutamyl transpeptidase with potential for reno-selective vasodilatation. Chemical Communications, 2013, 49, 1389.	4.1	7
42	Search for schizophrenia susceptibility variants at the HLA-DRB1 locus among a British population. Immunogenetics, 2013, 65, 1-7.	2.4	7
43	Emerging importance of omegaâ€3 fatty acids in the innate immune response: Molecular mechanisms and lipidomic strategies for their analysis. Molecular Nutrition and Food Research, 2013, 57, 1390-1400.	3.3	43
44	Development and Characterization of Glutamyl-Protected N-Hydroxyguanidines as Reno-Active Nitric Oxide Donor Drugs with Therapeutic Potential in Acute Renal Failure. Journal of Medicinal Chemistry, 2013, 56, 5321-5334.	6.4	8
45	Altered Nitric Oxide Bioavailability Contributes to Diesel Exhaust Inhalationâ€Induced Cardiovascular Dysfunction in Man. Journal of the American Heart Association, 2013, 2, e004309.	3.7	59
46	In vivo speciation studies and antioxidant properties of bromine in Laminaria digitata reinforce the significance of iodine accumulation for kelps. Journal of Experimental Botany, 2013, 64, 2653-2664.	4.8	49
47	Association between Exposure to Environmental Tobacco Smoke and Biomarkers of Oxidative Stress Among Patients Hospitalised with Acute Myocardial Infarction. PLoS ONE, 2013, 8, e81209.	2.5	19
48	Zeta Potential and Solubility to Toxic Ions as Mechanisms of Lung Inflammation Caused by Metal/Metal Oxide Nanoparticles. Toxicological Sciences, 2012, 126, 469-477.	3.1	251
49	NiO and Co3O4 nanoparticles induce lung DTH-like responses and alveolar lipoproteinosis. European Respiratory Journal, 2012, 39, 546-557.	6.7	74
50	Metalâ€“organic frameworks for the storage and delivery of biologically active hydrogen sulfide. Dalton Transactions, 2012, 41, 4060.	3.3	128
51	Differential pro-inflammatory effects of metal oxide nanoparticles and their soluble ions in vitro and in vivo ; zinc and copper nanoparticles, but not their ions, recruit eosinophils to the lungs. Nanotoxicology, 2012, 6, 22-35.	3.0	202
52	N-Acetylcysteine inhibits plateletâ€“monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Diabetologia, 2012, 55, 2920-2928.	6.3	44
53	Type 2 diabetes managed by diet and lifestyle: HbA_{1c} can identify significant postâ€prandial hyperglycaemia. Practical Diabetes, 2012, 29, 58-60.	0.3	1
54	Diabetic fatty liver disease is associated with specific changes in bloodâ€borne markers. Diabetes/Metabolism Research and Reviews, 2012, 28, 343-348.	4.0	1

#	Article	IF	Citations
55	Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol. BMC Clinical Pharmacology, 2012, 12, 3.	2.5	16
56	Photochemistry of trans-Cr(cyclam)(ONO)₂⁺, a Nitric Oxide Precursor. Inorganic Chemistry, 2011, 50, 4453-4462.	4.0	33
57	Diesel Exhaust Inhalation Induced Vascular Dysfunction: The Role Of Nitric Oxide. , 2011, , .		0
58	Food Intake and Dietary Glycaemic Index in Free-Living Adults with and without Type 2 Diabetes Mellitus. Nutrients, 2011, 3, 683-693.	4.1	9
59	The functional significance of the TGM2 gene in schizophrenia: A correlation of SNPs and circulating IL-2 levels. Journal of Neuroimmunology, 2011, 232, 5-7.	2.3	4
60	Differential susceptibility to nitric oxide-evoked apoptosis in human inflammatory cells. Free Radical Biology and Medicine, 2011, 50, 93-101.	2.9	9
61	Investigation of the Interaction Between the Ser447Term Polymorphism of Lipoprotein Lipase and the Stroke-Related Risk Factors in Ischemic Stroke. Translational Stroke Research, 2011, 2, 101-105.	4.2	0
62	Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Cardiovascular Diabetology, 2011, 10, 43.	6.8	46
63	Progressive severe lung injury by zinc oxide nanoparticles; the role of Zn2+ dissolution inside lysosomes. Particle and Fibre Toxicology, 2011, 8, 27.	6.2	342
64	Mechanisms of Resolution of Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1001-1006.	2.4	147
65	Surface Derivatization State of Polystyrene Latex Nanoparticles Determines both Their Potency and Their Mechanism of Causing Human Platelet Aggregation In Vitro. Toxicological Sciences, 2011, 119, 359-368.	3.1	63
66	Nitric Oxide Pathway Dysfunction Mediates Diesel Exhaust Inhalation Induced Vascular Dysfunction In Man. , 2010, , .		0
67	Genetic association of the AKT1 gene with schizophrenia in a British population. Psychiatric Genetics, 2010, 20, 118-122.	1.1	29
68	NO-loaded Zn2+-exchanged zeolite materials: A potential bifunctional anti-bacterial strategy. Acta Biomaterialia, 2010, 6, 1515-1521.	8.3	93
69	2â€arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors. British Journal of Clinical Pharmacology, 2010, 70, 180-188.	2.4	24
70	Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume. Human Molecular Genetics, 2010, 19, 1119-1128.	2.9	75
71	Metal Oxide Nanoparticles Induce Unique Inflammatory Footprints in the Lung: Important Implications for Nanoparticle Testing. Environmental Health Perspectives, 2010, 118, 1699-1706.	6.0	273
72	Acute Cardiovascular Effects of Apelin in Humans. Circulation, 2010, 121, 1818-1827.	1.6	281

#	Article	IF	Citations
73	Nitric Oxide Photogeneration from trans-Cr(cyclam)(ONO)₂⁺ in a Reducing Environment. Activation of Soluble Guanylyl Cyclase and Arterial Vasorelaxation. Journal of Medicinal Chemistry, 2010, 53, 715-722.	6.4	39
74	Direct Impairment of Vascular Function by Diesel Exhaust Particulate through Reduced Bioavailability of Endothelium-Derived Nitric Oxide Induced by Superoxide Free Radicals. Environmental Health Perspectives, 2009, 117, 611-616.	6.0	114
75	Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of proâ€inflammatory and antiâ€inflammatory agents: key role for TNFâ€±. FASEB Journal, 2009, 23, 844-854.	0.5	196
76	The TGM2 gene is associated with schizophrenia in a British population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 335-340.	1.7	11
77	Simultaneous Gas Storage and Catalytic Gas Production Using Zeolitesâ€"A New Concept for Extending Lifetime Gas Delivery. Topics in Catalysis, 2009, 52, 35-41.	2.8	20
78	Cyclic GMP protects human macrophages against peroxynitrite-induced apoptosis. Journal of Inflammation, 2009, 6, 14.	3.4	11
79	No association between the PPARG gene and schizophrenia in a British population. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 81, 273-277.	2.2	6
80	Evaluation of the Antioxidant Properties of N-acetylcysteine in Human Platelets: Prerequisite for Bioconversion to Glutathione for Antioxidant and Antiplatelet Activity. Journal of Cardiovascular Pharmacology, 2009, 54, 319-326.	1.9	48
81	NO and sGC-Stimulating NO Donors. Handbook of Experimental Pharmacology, 2009, , 247-276.	1.8	10
82	Endocannabinoid Blockade and the Cardiovascular System. Current Drug Therapy, 2009, 4, 111-116.	0.3	0
83	LA-419, a nitric-oxide donor for the treatment of cardiovascular disorders. Current Opinion in Investigational Drugs, 2009, 10, 276-85.	2.3	3
84	A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. Journal of Inflammation, 2008, 5, 12.	3.4	28
85	Exceptional Behavior over the Whole Adsorptionâ^'Storageâ^'Delivery Cycle for NO in Porous Metal Organic Frameworks. Journal of the American Chemical Society, 2008, 130, 10440-10444.	13.7	391
86	Vascular Effects of Apelin In Vivo in Man. Journal of the American College of Cardiology, 2008, 52, 908-913.	2.8	280
87	Curcumin Restores Corticosteroid Function in Monocytes Exposed to Oxidants by Maintaining HDAC2. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 312-323.	2.9	179
88	Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clinical Toxicology, 2008, 46, 697-702.	1.9	90
89	Simultaneous and cooperative gas storage and gas production using bifunctional zeolites. Chemical Communications, 2008, , 6146.	4.1	13
90	Endothelial Dysfunction: From Molecular Mechanisms to Measurement, Clinical Implications, and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2008, 10, 1631-1674.	5.4	159

#	Article	IF	Citations
91	Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L478-L488.	2.9	380
92	A genetic study of the NOS3 gene for ischemic stroke in a Chinese population. International Journal of General Medicine, 2008, 1, 65-8.	1.8	7
93	Persistent Endothelial Dysfunction in Humans after Diesel Exhaust Inhalation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 395-400.	5.6	334
94	Clearance of dying cells and autoimmunity. Autoimmunity, 2007, 40, 267-273.	2.6	38
95	Glutathione supplementation to University of Wisconsin solution causes endothelial dysfunction. Transplant Immunology, 2007, 18, 146-150.	1.2	3
96	High-Capacity Hydrogen and Nitric Oxide Adsorption and Storage in a Metalâ^'Organic Framework. Journal of the American Chemical Society, 2007, 129, 1203-1209.	13.7	546
97	Recent developments in nitric oxide donor drugs. British Journal of Pharmacology, 2007, 151, 305-321.	5.4	525
98	Topical application of acidified nitrite to the nail renders it antifungal and causes nitrosation of cysteine groups in the nail plate. British Journal of Dermatology, 2007, 157, 494-500.	1.5	15
99	Cigarette Smoking, Inflammation, and Obesity. , 2007, , 43-61.		0
100	NO-Releasing Zeolites and Their Antithrombotic Properties. Journal of the American Chemical Society, 2006, 128, 502-509.	13.7	230
101	Inducible nitric oxide synthase activity does not contribute to the maintenance of peripheral vascular tone in patients with heart failure. Clinical Science, 2006, 111, 275-280.	4.3	10
102	Apoptosis and Atherosclerosis: The Role of Nitric Oxide. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2006, 5, 27-33.	1.1	8
103	A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity. Journal of Inflammation, 2006, 3, 12.	3.4	1
104	Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. British Journal of Pharmacology, 2006, 148, 517-526.	5.4	51
105	Acoustic speed and attenuation coefficient in sheep aorta measured at 5-9 MHz. Ultrasound in Medicine and Biology, 2006, 32, 971-980.	1.5	9
106	Direct Vascular Effects of Protease-Activated Receptor Type 1 Agonism In Vivo in Humans. Circulation, 2006, 114, 1625-1632.	1.6	28
107	Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opinion on Therapeutic Targets, 2006, 10, 911-922.	3.4	14
108	A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. British Journal of Pharmacology, 2005, 144, 849-859.	5.4	50

#	Article	IF	Citations
109	Sildenafil offers protection against NSAID-induced gastric injury. British Journal of Pharmacology, 2005, 146, 477-478.	5.4	15
110	B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 772-777.	2.4	12
111	Zeolites for storage and delivery of nitric oxide in human physiology. Studies in Surface Science and Catalysis, 2005, , 2033-2040.	1.5	6
112	Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochemical and Biophysical Research Communications, 2005, 337, 382-385.	2.1	40
113	Depressed glutathione synthesis precedes oxidative stress and atherogenesis in Apo-Eâ^'/â^' mice. Biochemical and Biophysical Research Communications, 2005, 338, 1368-1373.	2.1	66
114	Curcumin Induces Glutathione Biosynthesis and Inhibits NF-ÎºB Activation and Interleukin-8 Release in Alveolar Epithelial Cells: Mechanism of Free Radical Scavenging Activity. Antioxidants and Redox Signaling, 2005, 7, 32-41.	5.4	329
115	Nitric oxide and the resolution of inflammation: implications for atherosclerosis. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 67-71.	1.6	19
116	GEA 3162 decomposes to co-generate nitric oxide and superoxide and induces apoptosis in human neutrophils via a peroxynitrite-dependent mechanism. British Journal of Pharmacology, 2004, 143, 179-185.	5.4	25
117	Extracellular Nitric Oxide Release Mediates Soluble Guanylate Cyclase-Independent Vasodilator Action of Spermine NONOate: Comparison with Other Nitric Oxide Donors in Isolated Rat Femoral Arteries. Journal of Cardiovascular Pharmacology, 2004, 43, 440-451.	1.9	15
118	Nitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death and Differentiation, 2003, 10, 418-430.	11.2	137
119	Nitric Oxide and the Mechanism of Rat Vascular Smooth Muscle Photorelaxation. Journal of Physiology, 2003, 550, 819-828.	2.9	20
120	Preserved endothelial vasomotion and fibrinolytic function in patients with acute stent thrombosis or in-stent restenosis. Thrombosis Research, 2003, 111, 343-349.	1.7	6
121	Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin. Journal of Medicinal Chemistry, 2003, 46, 747-754.	6.4	92
122	A novel S-nitrosothiol causes prolonged and selective inhibition of platelet adhesion at sites of vascular injury. Cardiovascular Research, 2003, 57, 853-860.	3.8	11
123	Novel Role for Low Molecular Weight Plasma Thiols in Nitric Oxide-mediated Control of Platelet Function. Journal of Biological Chemistry, 2002, 277, 46858-46863.	3.4	42
124	Non-Heme Iron Nitrosyls in Biology. Chemical Reviews, 2002, 102, 1155-1166.	47.7	324
125	The Effect of Oxidative Stress on Endothelium-Dependent and Nitric Oxide Donor-Induced Relaxation: Implications for Nitrate Tolerance. Nitric Oxide - Biology and Chemistry, 2002, 6, 263-270.	2.7	30
126	Nitric oxide donor drugs: current status and future trends. Expert Opinion on Investigational Drugs, 2002, 11, 587-601.	4.1	79

#	Article	IF	Citations
127	Lipophilic S-nitrosothiols: A means of targeted delivery of nitric oxide to areas of endothelial injury?. Drugs of the Future, 2002, 27, 777.	0.1	3
128	Dissociation of DNA Fragmentation from Other Hallmarks of Apoptosis in Nitric Oxide-Treated Neutrophils: Differences between Individual Nitric Oxide Donor Drugs. Biochemical and Biophysical Research Communications, 2001, 289, 1229-1236.	2.1	28
129	Acute Methionine Loading Does not Alter Arterial Stiffness in Humans. Journal of Cardiovascular Pharmacology, 2001, 37, 1-5.	1.9	29
130	Effects of acute methionine loading and vitamin C on endogenous fibrinolysis, endothelium-dependent vasomotion and platelet aggregation. Clinical Science, 2001, 100, 127.	4.3	11
131	Selective modifiers of glutathione biosynthesis and â€˜reprimingâ€™ of vascular smooth muscle photorelaxation. British Journal of Pharmacology, 2000, 130, 1575-1580.	5.4	35
132	Inducible nitric oxide synthase-derived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure. British Journal of Pharmacology, 2000, 131, 29-36.	5.4	36
133	Sâ€Nitrosothiols cause prolonged, nitric oxideâ€mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. British Journal of Pharmacology, 2000, 131, 1236-1244.	5.4	54
134	Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro : implications for anti-thrombotic therapy. British Journal of Pharmacology, 2000, 131, 1391-1398.	5.4	31
135	Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryl trinitrate-tolerant rat femoral arteries. European Journal of Pharmacology, 2000, 403, 111-119.	3.5	12
136	Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries. European Journal of Pharmacology, 2000, 408, 335-343.	3.5	31
137	A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clinical Pharmacology and Therapeutics, 2000, 68, 75-81.	4.7	14
138	Inhibition of Human Platelet Aggregation by Nitric Oxide Donor Drugs: Relative Contribution of cGMP-Independent Mechanisms. Biochemical and Biophysical Research Communications, 2000, 279, 412-419.	2.1	105
139	Nitric oxide donor drugs. Drugs of the Future, 2000, 25, 0701.	0.1	71
140	N-substituted analogues of S-nitroso- N -acetyl-D ,L -penicillamine: chemical stability and prolonged nitric oxide mediated vasodilatation in isolated rat femoral arteries. British Journal of Pharmacology, 1999, 126, 639-648.	5.4	48
141	S-nitrosothiols for nitrate tolerance. Lancet, The, 1999, 354, 338-339.	13.7	4
142	Oral Vitamin C Reduces Arterial Stiffness and Platelet Aggregation in Humans. Journal of Cardiovascular Pharmacology, 1999, 34, 690-693.	1.9	108
143	Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochimica Et Biophysica Acta - General Subjects, 1998, 1425, 168-176.	2.4	181
144	Synthesis, Decomposition, and Vasodilator Action of Some New S-Nitrosated Dipeptides. Nitric Oxide - Biology and Chemistry, 1998, 2, 193-202.	2.7	16

#	Article	IF	Citations
145	Therapeutic Potential of S-Nitrosothiols as Nitric Oxide Donor Drugs. Scottish Medical Journal, 1997, 42, 88-89.	1.3	8
146	Neocuproine, a selective Cu(I) chelator, and the relaxation of rat vascular smooth muscle by S -nitrosothiols. British Journal of Pharmacology, 1997, 121, 1047-1050.	5.4	61
147	Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases. British Journal of Pharmacology, 1997, 122, 1441-1449.	5.4	124
148	Prolonged effect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat femoral arteries: potential as a slow release nitric oxide donor drug. British Journal of Pharmacology, 1997, 122, 1617-1624.	5.4	39
149	Vasodilator responses of rat isolated tail artery enhanced by oxygenâ€dependent, photochemical release of nitric oxide from ironâ€sulphurâ€nitrosyls. British Journal of Pharmacology, 1996, 117, 1549-1557.	5.4	55
150	Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-dl-penicillamine and S-nitrosoglutathione. Bioorganic and Medicinal Chemistry, 1995, 3, 1-9.	3.0	79
151	Ironâ€sulphur cluster nitrosyls, a novel class of nitric oxide generator: mechanism of vasodilator action on rat isolated tail artery. British Journal of Pharmacology, 1992, 107, 842-848.	5.4	102